Handa Pharmaceuticals Inc.
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Tascenso ODT for the treatment of multiple sclerosis; and HND-033, HND-03… Read more
Market Cap & Net Worth: Handa Pharmaceuticals Inc. (6620)
Handa Pharmaceuticals Inc. (TWO:6620) has a market capitalization of $389.67 Million (NT$12.89 Billion) as of March 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #14028 globally and #466 in its home market, demonstrating a -3.77% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Handa Pharmaceuticals Inc.'s stock price NT$76.50 by its total outstanding shares 168530100 (168.53 Million).
Handa Pharmaceuticals Inc. Market Cap History: 2016 to 2026
Handa Pharmaceuticals Inc.'s market capitalization history from 2016 to 2026. Data shows change from $509.92 Million to $389.67 Million (-2.88% CAGR).
Handa Pharmaceuticals Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Handa Pharmaceuticals Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6620 by Market Capitalization
Companies near Handa Pharmaceuticals Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to Handa Pharmaceuticals Inc. by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Handa Pharmaceuticals Inc. Historical Marketcap From 2016 to 2026
Between 2016 and today, Handa Pharmaceuticals Inc.'s market cap moved from $509.92 Million to $ 389.67 Million, with a yearly change of -2.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$389.67 Million | -11.05% |
| 2025 | NT$438.06 Million | +14.97% |
| 2024 | NT$381.01 Million | -58.73% |
| 2023 | NT$923.18 Million | +49.49% |
| 2022 | NT$617.54 Million | +81.58% |
| 2021 | NT$340.09 Million | +176.41% |
| 2020 | NT$123.04 Million | -16.92% |
| 2019 | NT$148.09 Million | -4.98% |
| 2018 | NT$155.84 Million | -11.35% |
| 2017 | NT$175.80 Million | -65.52% |
| 2016 | NT$509.92 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Handa Pharmaceuticals Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $389.67 Million USD |
| MoneyControl | $389.67 Million USD |
| MarketWatch | $389.67 Million USD |
| marketcap.company | $389.67 Million USD |
| Reuters | $389.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.